Mr Allen, ACA, is currently Chairman of Proximagen Neuroscience plc, Chroma Therapeutics Limited and ProStrakan plc and a Non-Executive Director of Oxford Nanopore Technologies Limited and TMO Renewables Limited. Recently, Mr Allen has also been Acting CEO of ProStrakan Group plc until its sale earlier in 2011 and Chief Financial Officer of the electronics company Abacus Group plc from 2005 until the company was sold to Avnet Inc in January 2009. Prior to this he was Chief Financial Officer of Celltech Group plc between 1992 and 2004. In addition to managing Celltech 's flotation process in 1993, Mr Allen played a key role in several strategic acquisitions, including Chiroscience Group plc, Medeva plc and Oxford Glycosciences plc. In 2003 he was also appointed Deputy Chief Executive Officer of Celltech until the company was sold in 2004.
Stevie Spring, Future's Chief Executive, commented: "On behalf of the Board I would like to thank Roger Parry for more than a decade of service to Future. Personally, I have enjoyed working with him and thank him for his guidance and support."
"We are delighted to have attracted as his successor such an experienced Chairman as Peter Allen. He has an excellent track record as both director and chairman of public companies."
Peter Allen, Future's new Chairman commented: "Future's strategy has positioned it well for exciting growth in digital content and I look forward to accelerating its success."
Mr Parry will, as planned, step down from the Board at the end of the financial year.
